Thrombotic microangiopathy during carfilzomib use: case series in Singapore - Takeaways - MDSpire

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

  • By

  • Y Chen

  • M Ooi

  • S F Lim

  • A Lin

  • J Lee

  • C Nagarajan

  • C Phipps

  • Y S Lee

  • N F Grigoropoulos

  • Z Lao

  • S Surendran

  • E M Teh

  • Y T Goh

  • W J Chng

  • S K Gopalakrishnan

  • July 29, 2016

  • 0 min

Share

  • 1

    Carfilzomib is an effective treatment for multiple myeloma but has been associated with thrombotic microangiopathy (TMA) in some patients.

  • 2

    In a case series of 24 patients in Singapore, four cases of TMA were identified, resulting in a cumulative incidence of 16.7%.

  • 3

    Patients with TMA experienced symptoms such as anemia, thrombocytopenia, and acute kidney injury, leading to treatment discontinuation.

  • 4

    TMA occurred at doses of 56 mg/m2 and 27 mg/m2, with most patients managed expectantly and one requiring plasmapheresis.

  • 5

    This case series is the largest reported to date linking carfilzomib use to TMA, highlighting the need for careful monitoring.

Original Source(s)

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

  • by Y Chen, M Ooi, S F Lim, A Lin, J Lee, C Nagarajan, C Phipps, Y S Lee, N F Grigoropoulos, Z Lao, S Surendran, E M Teh, Y T Goh, W J Chng, S K Gopalakrishnan

  • July 29, 2016

Related Content

Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma